Clinical trials
Metastatic Solid Tumor clinical trials
Below are recruiting metastatic solid tumor clinical trials, each written for real people, not researchers. We’re tracking 1,102 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT01804634RecruitingPhase 2
Reduced-intensity stem cell transplant for high-risk solid tumors
This trial tests a less intense type of bone marrow (stem cell) transplant from a partly matched family donor for people with high-risk solid tumors. It aims to lower treatment intensity while still using the donor’s immune system to help control the cancer.
Baltimore, MarylandAges 1–50 - NCT07767474RecruitingPhase 1/Phase 2
Study of investigational drug for advanced solid tumors
This trial tests an experimental drug (ATX-898) alone or with other treatments for advanced solid tumors. It aims to see if the drug is safe and works against cancer, and it may be an option if you've already tried standard treatments.
Fort Worth, TexasAges 18 years+ - NCT05765851RecruitingPhase 1
A study of a new drug for advanced solid tumors with HER2
This trial tests a new combination treatment for people with advanced solid tumors that have HER2 changes. The goal is to see if it can shrink tumors or slow growth.
Sarasota, FloridaAges 18 years+ - NCT05204862RecruitingPhase 1/Phase 2
TU2218 drug with PD-1 therapy for advanced solid tumors
This Phase 1/2 study tests TU2218 by itself and with PD-1–type immunotherapy (anti–PD-(L)1) in people with advanced solid cancers. It’s designed to find a safe dose and see whether the treatment can shrink tumors when standard options have not worked.
San Antonio, TexasAges 18 years+ - NCT05911464RecruitingPhase 1
Study drug HS-10386 for advanced solid tumor cancers
This Phase 1 trial tests HS-10386 (an experimental treatment) in people with advanced solid tumors that can’t be cured with standard options. The goal is to find a safe dose and see how the cancer responds.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06072989RecruitingPhase 1
B4T2-001 CAR-T infusions for solid tumors without chemo
This trial tests a new kind of cell therapy called CAR-T that targets a protein called BT-001 on solid tumors. It uses repeat infusions and avoids the strong chemotherapy usually given before treatment, which may be easier to tolerate.
Shanghai, China/ShanghaiAges 18–70 - NCT06240546RecruitingPhase 1
Study of LPM6690176 for advanced solid tumors
This trial tests a new drug called LPM6690176 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if it is safe and how it affects the body.
BeijingAges 18–75 - NCT05909241RecruitingPhase 1
First study of BA1202 for advanced solid tumors
This Phase 1 study tests BA1202 in people with advanced solid cancers to find safe dosing and how the treatment may work. You may qualify if your cancer has progressed or you cannot use standard treatment, and—depending on the group—your tumor shows a specific marker called CEACAM5.
BeijingAges 18–70 - NCT05979155RecruitingPhase 1
Study of NWY001 for advanced solid tumors
This study tests a new experimental drug (NWY001) for people with advanced solid tumors that have stopped responding to standard treatments. It is a phase 1 trial, meaning it is early research to find the right dose and check for side effects.
Guangzhou, GuangdongAges 18–75 - NCT06332170RecruitingPhase 1
HS-20093 combination safety study for advanced solid tumors
This study tests a new combination drug called HS-20093 for people with advanced solid tumors. It aims to see if it is safe and works against cancer that hasn't responded to other treatments.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06514651RecruitingPhase 1
MAQ-001 for advanced solid tumors after PD-1/PD-L1 therapy
This study tests a new experimental drug called MAQ-001 in people with advanced solid tumors or lymphomas that have already been treated with a PD-1/PD-L1 checkpoint inhibitor. The goal is to see if MAQ-001 can shrink or control the cancer when other treatments are no longer working.
LyonAges 18 years+ - NCT06257680RecruitingPhase 1
ReT01 cell therapy for advanced solid tumors
This trial tests a new cell therapy called ReT01 for people with advanced solid tumors that have stopped responding to standard treatments. It uses your own immune cells from a tumor sample to fight the cancer.
Beijing, Beijing MunicipalityAges 18–75 - NCT06525298RecruitingPhase 1/Phase 2
Study of EIS-12656 for solid tumors with DNA repair defects
This trial tests a new drug, EIS-12656, alone or with other treatments, for solid tumors that have specific DNA repair problems called homologous recombination deficiency. It may be an option if your cancer has not responded to prior treatments.
Houston, TexasAges 18 years+ - NCT07749586RecruitingPhase 1/Phase 2
Study of ARV-6723 alone or with pembrolizumab for advanced solid tumors
This trial tests an experimental drug called ARV-6723, alone or with another drug called pembrolizumab, for people with advanced solid tumors that have not responded to other treatments. The goal is to see if these combinations can help shrink tumors or slow their growth.
New York, New YorkAges 18 years+ - NCT07744763RecruitingPhase 1/Phase 2
Study of SYS6041 for advanced solid tumors
This trial tests a new drug called SYS6041 for people with certain advanced cancers that have not responded to standard treatments. It targets a protein called FRα found on some tumor cells, which may help the drug attack the cancer more effectively.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06615193RecruitingPhase 1
Testing a new drug for certain blood and solid tumors
This study tests a new drug, HDM2005, for people with relapsed or hard-to-treat B-cell lymphoma or advanced solid tumors. The goal is to see if it is safe and effective.
Zhengzhou, HenanAges 18 years+ - NCT07719920RecruitingPhase 1
Study of HW221043 for advanced solid tumors
This trial is testing a new oral drug called HW221043 for people with advanced solid tumors that have not responded to other treatments. The goal is to see if it is safe and how well it works.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT04387916RecruitingPhase 1
Test drug KC1036 in people with advanced solid tumors
This Phase 1 trial studies how a new medicine (KC1036) works and how safe it is for people with advanced solid cancers that have grown despite standard treatments. It may help future patients by showing whether the drug can control cancer in difficult-to-treat cases.
Chongqing, Chongqing MunicipalityAges 18 years+ - NCT04093466RecruitingPhase 1
Testing a new pill for advanced solid tumors
This Phase 1 trial tests kanitinib (CX1003), a new cancer medicine, in people with advanced solid tumors that have come back or stopped responding to standard treatment. The goal is to find a safe dose and see early signs of tumor response.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07667842RecruitingPhase 1
Study of D3L-002 for advanced solid tumors
This trial tests a new drug, D3L-002, for people with advanced solid tumors that have stopped responding to at least one prior treatment or have no standard options. The goal is to see if it can help shrink or control the cancer.
Macquarie ParkAges 18 years+ - NCT07639047RecruitingPhase 1
Testing AN8025 in Advanced Solid Cancers
This early-stage trial tests a new drug called AN8025 in people with advanced solid tumors (cancers that started in organs or tissues). The study aims to find the right dose and see if it helps patients whose cancers have grown despite other treatments.
Nedlands, Western AustraliaAges 18 years+ - NCT06084286RecruitingPhase 1
CAR-T therapy targeting CLDN18.2 and PD-L1 for advanced solid tumors
This trial tests a new type of cell therapy (CAR-T) that targets two proteins, CLDN18.2 and PD-L1, found on some cancer cells. It is for people with advanced solid tumors like stomach, esophageal, or pancreatic cancer that have stopped responding to standard treatments.
Chengdu, SichuanAges 18–75 - NCT07617493RecruitingPhase 1/Phase 2
ICP-B208 for Advanced Solid Tumors
This early-stage trial tests a new cancer drug called ICP-B208 in people with advanced solid tumors (like stomach, colon, or other cancers) that have spread or cannot be removed surgically and have not responded to previous treatments. The study aims to find the right dose and see how well the drug works.
Beijing, Beijing MunicipalityAges 18–75 - NCT06112704RecruitingPhase 2
HS-20093 for advanced esophageal and other solid tumors
This trial tests an investigational drug called HS-20093 for people with advanced esophageal cancer or other solid tumors that have not responded to prior treatment. The drug targets a protein on cancer cells called B7-H3, and the study aims to see if it can shrink tumors or slow their growth.
Hefei, AnhuiAges 18 years+
Hear when a new Metastatic Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for metastatic solid tumor?
- Yes. Clin2 currently lists 1,102 recruiting metastatic solid tumor studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a metastatic solid tumor trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a metastatic solid tumor trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.